Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A Murine tumor model

Miles W. Carroll, Willem W. Overwijk, Ronald S. Chamberlain, Steven A. Rosenberg, Bernard Moss, Nicholas P. Restifo

Research output: Contribution to journalArticle

Abstract

Modified vaccinia virus Ankara (MVA), a highly attenuated strain of vaccinia virus (VV) that is unable to replicate in most mammalian cells, was evaluated as an expression vector for a model tumor associated antigen (TAA) and as a potential anti-cancer vaccine. We employed an experimental murine model in which an adenocarcinoma tumor line, CT26.CL25, was stably transfected with a model TAA, β-galactosidase (β-gal). Mice injected intramuscularly with a recombinant MVA (rMVA) expressing β-gal (MVA-LZ), were protected from a lethal intravenous (i.v.) challenge with CT26.CL25. In addition, splenocytes from mice primed with MVA-LZ were therapeutically effective upon adoptive transfer to mice bearing pulmonary metastases of the CT26.CL25 tumor established 3 days earlier. Most importantly, i.v. inoculation with MVA-LZ resulted in significantly prolonged survival of mice bearing three day old pulmonary metastases. This prolonged survival compared favorably to mice treated with a replication competent recombinant VV expressing β-gal. These findings indicate that rMVA is an efficacious alternative to the more commonly used replication competent VV for the development of new recombinant anti-cancer vaccines.

Original languageEnglish (US)
Pages (from-to)387-394
Number of pages8
JournalVaccine
Volume15
Issue number4
DOIs
StatePublished - Mar 1 1997

Keywords

  • cancer immunotherapy
  • modified vaccinia virus Ankara (MVA)
  • vaccinia virus

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A Murine tumor model'. Together they form a unique fingerprint.

  • Cite this

    Carroll, M. W., Overwijk, W. W., Chamberlain, R. S., Rosenberg, S. A., Moss, B., & Restifo, N. P. (1997). Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A Murine tumor model. Vaccine, 15(4), 387-394. https://doi.org/10.1016/S0264-410X(96)00195-8